To the Editor:The current coronavirus disease-19(COVID-19)pandemic spurs the development of antiviral drugs for SARS-CoV-2,as the number of patients with viral infections continues to rise globally in the context of w...To the Editor:The current coronavirus disease-19(COVID-19)pandemic spurs the development of antiviral drugs for SARS-CoV-2,as the number of patients with viral infections continues to rise globally in the context of widespread vaccination.Targeting the interaction between the receptor binding domain(RBD)of SARS-CoV-2 spike protein and the host cell ACE2 is a promising therapeutic strategy to effectively inhibit viral entry.展开更多
基金supported by the National Natural Science Foundation of China (22078314, 21878286, 21908216)Dalian Institute of Chemical Physics (DICPI202142, DICPI202006, DICPI201938, DICPZZBS201805, China)
文摘To the Editor:The current coronavirus disease-19(COVID-19)pandemic spurs the development of antiviral drugs for SARS-CoV-2,as the number of patients with viral infections continues to rise globally in the context of widespread vaccination.Targeting the interaction between the receptor binding domain(RBD)of SARS-CoV-2 spike protein and the host cell ACE2 is a promising therapeutic strategy to effectively inhibit viral entry.
